PRA Health Sciences (PRAH) Hits New 12-Month High at $84.61
PRA Health Sciences, Inc. (NASDAQ:PRAH) reached a new 52-week high during trading on Tuesday . The company traded as high as $84.61 and last traded at $83.75, with a volume of 503400 shares trading hands. The stock had previously closed at $82.71.
PRAH has been the topic of several research analyst reports. Jefferies Group reissued a “buy” rating and issued a $95.00 target price on shares of PRA Health Sciences in a research note on Thursday, October 26th. Zacks Investment Research lowered shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Tuesday, August 29th. KeyCorp reissued a “buy” rating and issued a $93.00 target price (up from $86.00) on shares of PRA Health Sciences in a research note on Monday, October 30th. Robert W. Baird set a $94.00 target price on shares of PRA Health Sciences and gave the stock a “buy” rating in a research note on Friday, December 1st. Finally, Credit Suisse Group reissued an “outperform” rating and issued a $90.00 target price (up from $84.00) on shares of PRA Health Sciences in a research note on Monday, October 16th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $89.50.
The stock has a market cap of $5,360.00, a P/E ratio of 30.41, a P/E/G ratio of 1.43 and a beta of 0.40. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 1.38.
PRA Health Sciences (NASDAQ:PRAH) last issued its earnings results on Wednesday, October 25th. The medical research company reported $0.88 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.03. The firm had revenue of $494.55 million during the quarter, compared to the consensus estimate of $477.89 million. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The company’s revenue was up 23.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.64 earnings per share. analysts anticipate that PRA Health Sciences, Inc. will post 3.2 earnings per share for the current year.
In related news, Director Matthew P. Young sold 5,115 shares of the business’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $79.90, for a total value of $408,688.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.10% of the stock is owned by insiders.
Several large investors have recently made changes to their positions in PRAH. Aperio Group LLC purchased a new position in PRA Health Sciences during the second quarter worth about $233,000. Sei Investments Co. raised its holdings in PRA Health Sciences by 4.9% during the second quarter. Sei Investments Co. now owns 14,654 shares of the medical research company’s stock worth $1,100,000 after purchasing an additional 690 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in PRA Health Sciences by 10.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 234,930 shares of the medical research company’s stock worth $17,623,000 after purchasing an additional 22,303 shares in the last quarter. First Trust Advisors LP raised its holdings in PRA Health Sciences by 21.1% during the second quarter. First Trust Advisors LP now owns 100,399 shares of the medical research company’s stock worth $7,531,000 after purchasing an additional 17,519 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in PRA Health Sciences by 48.5% during the second quarter. Rhumbline Advisers now owns 44,149 shares of the medical research company’s stock worth $3,312,000 after purchasing an additional 14,413 shares in the last quarter. 98.49% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “PRA Health Sciences (PRAH) Hits New 12-Month High at $84.61” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.watchlistnews.com/pra-health-sciences-prah-hits-new-12-month-high-at-84-61/1759992.html.
About PRA Health Sciences
PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with Analyst Ratings Network's FREE daily email newsletter.